Cancer Research Institute meets the 20 Standards for Charity Accountability.
CRI funds research at academic centers around the world through fellowships, grants, and clinical trials focused on increasing the understanding of the immune system and with the goal of developing immunological methods for the prevention and treatment of cancer. CRI also provides information to the public about cancer immunotherapy, and connects patients to immunotherapy clinical trials.
For the year ended June 30, 2017, Cancer Research Institute's program expenses were:
Research |
$16,442,792 |
Science, medical and research information, and communications |
$4,756,607 |
Total Program Expenses: |
$21,199,399 |
-
Chief Executive
Jill O'Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs
-
Compensation*
$449,858
-
Chair of the Board
Paul Shiverick
-
Chair's Profession / Business Affiliation
Investment firm partner
-
Board Size
36
-
Paid Staff Size
24
**016 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Grant proposals, Internet, Invitations to fund raising events, Planned giving arrangements, Radio, Cause- related marketing (affinity credit cards, consumer product sales, etc.)
Fundraising costs were 12% of related contributions. (Related contributions, which totaled $22,969,160, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c) (3) of the Internal Revenue Code.It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on Cancer Research Institute's audited financial statements for the year ended June 30, 2017.
Source of Funds |
Designated contributions |
$10,926,243 |
General, trustee, and related |
$6,368,910 |
Investment income in excess of investment allocation, net |
$3,769,886 |
Bequests/memorials |
$2,475,218 |
Special events, net |
$2,442,606 |
Investment income allocation |
$2,154,376 |
Combined federal campaigns |
$756,183 |
Miscellaneous |
$91,215 |
Change in value of perpetual trust |
$31,194 |
Total Income |
$29,015,831 |
- Programs: 84%
- Fundraising: 11%
- Administrative: 5%
Total Income |
$29,015,831 |
Program expenses |
$21,199,399 |
Fundraising expenses |
$2,811,152 |
Administrative expenses |
$1,287,157 |
Other expenses |
$0 |
Total expenses: |
$25,297,708 |
Income in Excess of Expenses |
$3,718,123 |
Beginning Net Assets |
$53,653,098 |
Other Changes In Net Assets |
$-2,675,301 |
Ending Net Assets |
$54,695,920 |
Total Liabilities |
$55,370,755 |
Total Assets |
$110,066,675 |
Note 1: According to CRI's audited financial statements for the fiscal year ended June 30, 2017, the organization received in-kind contributions totaling $959,546 in the form of contributed services by the Institut's Scientific Advisory Council. Note 2: In the financial section above, '"other expenses" refers to allowance for uncollectible amounts. Note 3: In the financial section above, "other changes in net assets" refers to allowance for uncollectible accounts (-$2,615,201) and a rental loss, net (-$60,100).